The immunogenicity, safety, and efficacy of etanercept liquid administered once weekly in patients with rheumatoid arthritis

To evaluate the immunogenicity, safety, and efficacy of 50 mg/mL liquid etanercept. In a multicenter, open-label study, adults with active rheumatoid arthritis (RA) received 50 mg/mL liquid etanercept subcutaneously once weekly for 24 weeks. Immunogenicity was assessed at baseline and weeks 24 and 2...

Full description

Saved in:
Bibliographic Details
Published in:Clinical and experimental rheumatology 2007, Vol.25 (1), p.40-46
Main Authors: DORE, R. K, MATHEWS, S, SCHECHTMAN, J, SURBECK, W, MANDEL, D, PATEL, A, ZHOU, L, PELOSO, P
Format: Article
Language:English
Subjects:
Adult
Aged
Aged, 80 and over
Antibody Formation - drug effects
Antibody Formation - immunology
Arthritis, Rheumatoid - drug therapy
Biological and medical sciences
Diseases of the osteoarticular system
Drug Administration Schedule
Drug Compounding
Etanercept
Female
Humans
Immunoglobulin G - adverse effects
Immunoglobulin G - immunology
Immunoglobulin G - pharmacology
Immunoglobulin G - therapeutic use
Immunologic Factors - adverse effects
Immunologic Factors - immunology
Immunologic Factors - therapeutic use
Immunomodulators
Inflammatory joint diseases
Injections, Subcutaneous
Male
Medical sciences
Middle Aged
Pain Measurement
Pharmacology. Drug treatments
Receptors, Tumor Necrosis Factor - immunology
Receptors, Tumor Necrosis Factor - therapeutic use
Severity of Illness Index
Treatment Outcome
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:To evaluate the immunogenicity, safety, and efficacy of 50 mg/mL liquid etanercept. In a multicenter, open-label study, adults with active rheumatoid arthritis (RA) received 50 mg/mL liquid etanercept subcutaneously once weekly for 24 weeks. Immunogenicity was assessed at baseline and weeks 24 and 28, safety at all study visits, and efficacy at baseline and weeks 12 and 24. Of 222 treated patients, 88% completed the study; 81% were women; 84% were white; mean age was 53 years; mean RA duration was 10 years. Antibodies to etanercept, all non-neutralizing, were detected in 12 of 214 patients; 7 of the 12 were borderline positive (antibody titers
ISSN:0392-856X
1593-098X